Concepedia

Author

C Cohen

Community Research Initiative

Also Known As

C COHEN, C Cohen, C J Cohen, C. Cohen, C.J. Cohen, Calvin Cohen, Cavin J. Cohen, T Fiore

26

Publications

425

Citations

11

H-Index

32

Concepts

All Affiliations

Community Research InitiativeBristol-Myers Squibb (United States)Orlando Immunology CenterWhitman-Walker HealthGilead Sciences (United States)
CC

About

C Cohen is an author at Community Research Initiative specializing in pharmacotherapy, medicine, and hiv.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

126

2

Public Health

2

2

22

3

Health Sciences

1

1

55

4

Epidemiology

1

1

11

5

Health Policy

1

1

11

C Cohen

×

9

Publications

331

Citations

9

H-Index

YearCitations

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

C Cohen, Leopoldo Nieto‐Cisneros, Carlos Zala,

Current Medical Research and Opinion

2005

93

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

Mark Nelson, Richard Elion, C Cohen,

HIV Clinical Trials

2013

60

Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.

Kenneth A. Freedberg, Anna N.A. Tosteson, C Cohen,

PubMed

1991

55

Long-Term Treatment with Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily Living

C Cohen, Alex Dusek, J. Green,

AIDS Patient Care and STDs

2002

38

The prevalence of transmitted antiretroviral drug resistance in treatment‐naïve patients and factors influencing first‐line treatment regimen selection

H.‐Y. HUANG, ES Daar, Barnaby Edward Young,

HIV Medicine

2008

26

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

Rafael Campo, C Cohen, Kristy Grimm,

International Journal of STD & AIDS

2010

26

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

Andrew Zolopa, Joel E. Gallant, C Cohen,

Journal of the International AIDS Society

2012

11

Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population

C Cohen, Kevin Davis, Juliana Meyers

Journal of the International AIDS Society

2012

11

O214 The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy

C Cohen, Amy E. Colson, Gerald Pierone,

Journal of the International AIDS Society

2008

11

Page 1